AGPU AGPU Drug Discovery Services — Research And Development Expense

Other segment segments

Similar metrics at other companies

DNTHDiscovery Expenses — Research And Development Expense

$1.36M+51.4%

KURADiscovery Stage Program — Research And Development Expense

$1.4M-33.0%

INVAExternal Services — Research And Development Expense

$2.61M-14.6%

OPKPharmaceutical — Research And Development Expense

$28.75M-4.9%

BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)

$3.97M+30.4%

SDGRDrug Discovery Services — Drug discovery services revenue from contracts with customers

$11.7M+105%

Questions, answered.

What is AGPU's drug discovery services — research and development expense?

AGPU (AGPU) reported drug discovery services — research and development expense of $2.14M in Q4 2025.

How has AGPU's drug discovery services — research and development expense changed year-over-year?

AGPU's drug discovery services — research and development expense increased by 282.6% year-over-year, from $558.63K to $2.14M.

What does drug discovery services — research and development expense mean?

Represents the costs incurred by the Drug Discovery Services segment to innovate, develop new proprietary models, or improve existing service methodologies. This is a critical investment metric for a healthcare-focused firm, signaling the segment's commitment to future growth and competitive differentiation. It reflects the intensity of the segment's focus on scientific advancement.